OGR for PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA)
What was lobbied
3 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Issues related to Medicare Part D access and drug pricing negotiation, compulsory licensing policy, and insulin policy.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Trade (domestic/foreign) TRD
Issues related to WTO TRIPS. Intellectual property issues.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Health Issues HCR
General provisions related to the pharmaceutical industry including prescription drug affordability and access, intellectual property, privacy, 340B drug discount program policy, and clinical trial diversity issues; FY2025 Appropriations Process monitoring; Implementation of H.R.5376, Inflation Reduction Act of 2022 (P.L.117-169); Issues related to the role of pharmacy benefit managers in drug pricing including H.R.6283, DRUG Act.
| Lobbyist | Covered position, as disclosed |
|---|---|
| DEAN AGUILLEN | — |
| JEROME MURRAY | — |
| KARISSA WILLHITE | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.